Observational Study to Collect Data and Blood Biomarkers in Men with Metastatic Prostate Cancer Treated with Lutetium-PSMA Therapy

What this Trial Is About

Researchers are collecting data from patients with metastatic prostate cancer who are receiving Lutetium-PSMA Lu-PSMA therapy. The study aims to gather real-world information on how effective and safe this treatment is, as well as to collect dosimetry and biomarker data. This will help identify which patients benefit most from Lu-PSMA therapy. The study involves collecting blood samples during routine clinical visits to analyze circulating tumor DNA ctDNA and circulating tumor cells. These samples, along with PSMA-PET scans, will be used to evaluate response to treatment and explore biomarkers. There is no intervention beyond standard care the study is observational and focuses on data collection. Participants will be monitored for up to 44 months to assess overall survival and progression-free survival. Researchers will also study the heterogeneity of PSMA positivity, the effect of biomarkers on treatment response, and scan data. The study is sponsored by Erasmus Medical Center and involves regular clinical follow-ups and blood draws as part of routine care.

Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics